Shield Therapeutics PLC - Feraccru: a potential game changer in the treatment of iron deficiency anaemia
Feraccru is a unique, non-salt, formulation oral iron: strong efficacy with “placebo-like” tolerability
Potential to change iron deficiency anaemia (IDA) therapeutic algorithm
Feraccru to become the preferred option for patients not adequately controlled or who are intolerant to generic oral iron supplements (before they switch to intravenous iron).
With an indication in Europe to treat iron deficiency, Feraccru’s use would prevent the occurrence/reoccurrence of iron deficiency anaemia
Feraccru European commercialisation expected to accelerate significantly following the licensing agreement with Norgine announced in September 2018
Key upcoming milestones: results of the head-to-head phase 3 study of Feraccru vs intravenous (i.v.) iron expected in first half (1H) of 2019; Feraccru PDUFA (Prescription Drug User Fee Act) date 27 July 2019
Current market capitalisation of about £40mln is by and large not reflecting Feraccru commercial potential
Shield’s lead asset Feraccru is a novel and highly differentiated iron formulation, for oral administration, indicated for the treatment of iron deficiency, i.e. low levels of iron body stores, usually caused by blood loss or malabsorption.
Quick facts: Shield Therapeutics PLC
Price: 88 GBX
Market Cap: £103.13 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE